Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sleepman who wrote (299)	7/29/1997 10:56:00 PM
From: Ed Ajootian	of 10280

Dan, J&J's composition-of-matter patent on astemizole expires next year. It is generally thought that a composition-of-matter patent on a compound also covers its active metabolite. J&J also has a method-of-use patent running out to 2006, which SEPR considers to be very weak. SEPR has filed for method-of-use patents in the US and several other companies but has yet to get any issued. The key here is that there will not be a composition-of-matter patent or a strong method-of-use patent owned by anyone else when norastemizole is approved ('99 at the earliest). So the field is wide open for SEPR. Nice to see the solid recovery today. Looking for a gradual move back up knocking on the door to new highs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next